Clinical Trials
35 trialsNCT01373710 2025-11-24
HIT
Institut Curie
Phase 1/2 Completed
NCT00317720 2025-04-30
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01084863 2025-01-24
Compare
Celltrion
Phase 1/2 Completed
NCT02066532 2023-08-24
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Columbia University
Phase 1/2 Completed
NCT00337649 2023-04-28
A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 1/2 Completed
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01922921 2023-04-18
Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
University of Washington
Phase 1/2 Completed
NCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT00129896 2023-03-06
Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT02657343 2022-08-01
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00238420 2022-07-19
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02139358 2021-02-04
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01271920 2020-12-08
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Novartis
Phase 1/2 Completed
NCT00574587 2020-10-14
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Albert Einstein College of Medicine
Phase 1/2 Completed
NCT00033514 2020-10-08
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT02120911 2020-07-01
TRAP
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT01325207 2019-09-26
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Northwestern University
Phase 1/2 Completed
NCT02843126 2019-09-12
Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Completed
NCT00923299 2019-04-16
THERAPY
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT00398567 2018-07-24
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00331552 2017-07-26
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
University of Washington
Phase 1/2 Completed
NCT00086957 2017-02-27
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT00458237 2016-10-20
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00450892 2016-07-07
Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT01042925 2016-06-03
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Sanofi
Phase 1/2 Completed
NCT01746771 2016-03-03
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Hanmi Pharmaceutical Company Limited
Phase 1/2 Completed
NCT00095706 2015-09-25
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Translational Oncology Research International
Phase 1/2 Completed
NCT02015676 2015-03-12
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 1/2 Completed
NCT01386580 2015-01-22
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
Phase 1/2 Completed
NCT00258349 2014-06-02
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00004925 2013-06-19
Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00788333 2012-07-13
Combination Study of BMS-754807 and HerceptinĀ® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00006108 2012-02-07
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00031278 2011-05-30
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed
NCT00006825 2011-03-28
Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer
NYU Langone Health
Phase 1/2 Completed